- Roche expands trial of Alzheimer's drug gantenerumab
Roche Holding decided to increase from 360 to 770 the number of patients participating in a trial of investigational Alzheimer's disease drug gantenerumab, after setbacks by rivals. "The playing field has changed dramatically, and gantenerumab is now the most advanced monoclonal antibody in early Alzheimer's and the next big news to read out in this space," said Luca Santarelli, Roche's neuroscience head. The firm expects results of the trial, which involves patients who have yet to develop dementia, to be released in 2015. Reuters (9/7)        | Webinar: Complete Quality Management System Across the Enterprise - Thursday, 9/13 - 2:00pm EDT
Companies across the pharmaceutical and biotechnology industries need to protect their brands and reputations by delivering safe, effective, high quality products to the global market. Deploying a true enterprise quality management system has the inherent ability to harmonize all quality processes from each functional area, across all regions, and throughout the critical supplier network. Register Now! | |
| Health Care & Policy |  |  | | - Peregrine's bavituximab boosts survival in lung cancer trial
Nonsmall-cell lung cancer patients who received Peregrine Pharmaceuticals' drug candidate bavituximab in combination with traditional chemotherapy showed median survival of 12.1 months in a midstage study, more than double the rate among those on chemotherapy alone. The firm plans to meet with the FDA ahead of a Phase III trial by the middle of next year. Bloomberg Businessweek (9/7)  | Earn 2X rewards points on shipping costs with The Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, and shipping
• 1X points on everything else
• Limited Time Offer: 50K bonus points when you spend $5K in your first 3 months of Card membership†
LEARN MORE AND APPLY †Terms & Restrictions Apply. |
  | Company & Financial News | | | | - Galenea's schizophrenia research wins $3M grant from NIMH
The National Institute of Mental Health awarded a $3 million grant to Galenea and a research partner at the VA Boston Healthcare System and Harvard Medical School. The goal of the five-year grant is to advance the use of electroencephalography in preclinical studies of schizophrenia drugs by identifying differences and similarities in the brain activity of humans and rodents. Mass High Tech (Boston) (9/7) | Drug Development & Manufacture Basic Training | | | | - How to improve cycle times
Recently developed immunoassay technology platforms can help to reduce sample volume requirements and improve cycle times. Here, advice on how to compress drug development timelines using accelerated immunoassays. Get more free content like this by subscribing to BioPharm International. BioPharm International (8/2012)
 | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| Food & Agriculture | | | | | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - BP Biofuels and partner to develop energy crops for Gulf Coast
BP Biofuels has teamed up with Texas AgriLife Research on a three-year project to develop energy crops that can be grown commercially on the Gulf Coast. The project's goal is "to develop a pipeline of genetics for biomass feedstocks and production guidelines," said Tom Campbell, BP Biofuels' vice president for technology. The initiative will focus on new varieties of pearl millet, napier grass, king grass, energy cane and miscane, Texas AgriLife Research said. BiomassMagazine.com (9/6) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | Spend the afternoon. You can't take it with you."
--Annie Dillard,
American author  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, September 07, 2012
- Thursday, September 06, 2012
- Wednesday, September 05, 2012
- Tuesday, September 04, 2012
- Friday, August 31, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment